Exchange: NASDAQ·Updated 08:11 AM EDT
ATRC logo

ATRCAtricure Inc

$28.20
$0.2397
(0.84%)
Pre-Market
Prev Close $28.44
EarningsJul 28
Mkt Cap$1.44B
Vol20.00
News
all
press releases
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks
News Placeholder
More News
News Placeholder
Do Options Traders Know Something About AtriCure Stock We Don't?
Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
Zacks
News Placeholder
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 47th Annual Global...
Business Wire
News Placeholder
AtriCure (ATRC) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
News Placeholder
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
News Placeholder
AtriCure (NASDAQ:ATRC) Releases FY 2026 Earnings Guidance
AtriCure (NASDAQ:ATRC) updated its FY 2026 earnings guidance. The company provided EPS guidance of 0.000-0.040 for the period, compared to the consensus estimate of 0.130. The company also issued revenue guidance of $600.0 millionillion-$610.0 millionillion, compared to the consensus estimate of...
MarketBeat
News Placeholder
AtriCure Q1 Earnings Call Highlights
AtriCure (NASDAQ:ATRC) reported first-quarter 2026 results that management described as an accelerated growth start to the year, highlighted by double-digit revenue gains and improved profitability...
MarketBeat
News Placeholder
AtriCure (ATRC) Reports Break-Even Earnings for Q1
AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
AtriCure Reports First Quarter 2026 Financial Results
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management...
Business Wire
News Placeholder
AtriCure (NASDAQ:ATRC) Reaches New 52-Week Low - What's Next?
AtriCure (NASDAQ:ATRC) Sets New 52-Week Low - What's Next...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.